Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	$2.95M	N/A	N/A	N/A
FPRX Five Prime Therapeutics	$38.00	$37.94	$2.61 ▼ $38.90	$1.77B	4.4	1.98 million shs	N/A
MNPR Monopar Therapeutics	$43.73 +18.6%	$35.56	$1.72 ▼ $54.30	$267.63M	1.01	361,920 shs	124,760 shs
NATR Nature's Sunshine Products	$15.79 +1.1%	$14.65	$10.81 ▼ $18.06	$291.48M	1.14	51,326 shs	73,525 shs
OVID Ovid Therapeutics	$0.40 -2.0%	$0.31	$0.24 ▼ $1.47	$28.22M	0.13	447,631 shs	443,469 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
FPRX Five Prime Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MNPR Monopar Therapeutics	0.00%	+2.79%	+9.99%	-1.65%	+936.11%
NATR Nature's Sunshine Products	0.00%	+0.32%	+8.32%	+28.98%	+3.99%
OVID Ovid Therapeutics	0.00%	+17.73%	+44.54%	+41.11%	-57.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARAV Aravive	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.1839 of 5 stars	3.4	2.0	0.0	0.0	3.2	1.7	0.0
NATR Nature's Sunshine Products	1.7025 of 5 stars	2.5	3.0	0.0	0.0	2.5	2.5	0.0
OVID Ovid Therapeutics	4.7233 of 5 stars	3.6	5.0	0.0	4.6	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARAV Aravive	0.00	N/A	N/A	N/A
FPRX Five Prime Therapeutics	0.00	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	37.21% Upside
NATR Nature's Sunshine Products	3.00	Buy	$18.33	16.11% Upside
OVID Ovid Therapeutics	3.20	Buy	$3.13	687.35% Upside

Current Analyst Ratings Breakdown

Latest FPRX, ARAV, MNPR, NATR, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/3/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/7/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARAV Aravive	$9.14M	0.32	N/A	N/A	N/A	∞
FPRX Five Prime Therapeutics	$14.87M	119.01	N/A	N/A	$4.13 per share	9.20
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
NATR Nature's Sunshine Products	$454.36M	0.64	$1.26 per share	12.50	$8.71 per share	1.81
OVID Ovid Therapeutics	$570K	49.52	N/A	N/A	$0.96 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARAV Aravive	-$76.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	-$137.20M	-$3.92	N/A	N/A	N/A	-554.71%	-75.84%	-49.08%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
NATR Nature's Sunshine Products	$7.70M	$0.53	29.79	∞	N/A	2.22%	6.98%	4.63%	8/6/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)

Latest FPRX, ARAV, MNPR, NATR, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	N/A	MNPR Monopar Therapeutics	-$0.47	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/6/2025	Q1 2025	NATR Nature's Sunshine Products	$0.16	$0.25	+$0.09	$0.25	$109.39 million	$113.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARAV Aravive	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
NATR Nature's Sunshine Products	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARAV Aravive	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	5.35	5.35
MNPR Monopar Therapeutics	N/A	36.91	36.91
NATR Nature's Sunshine Products	N/A	2.41	1.50
OVID Ovid Therapeutics	0.22	4.93	4.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARAV Aravive	35.80%
FPRX Five Prime Therapeutics	67.28%
MNPR Monopar Therapeutics	1.83%
NATR Nature's Sunshine Products	79.40%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
ARAV Aravive	60.40%
FPRX Five Prime Therapeutics	6.40%
MNPR Monopar Therapeutics	20.50%
NATR Nature's Sunshine Products	5.60%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARAV Aravive	20	73.56 million	29.13 million	No Data
FPRX Five Prime Therapeutics	87	46.57 million	N/A	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
NATR Nature's Sunshine Products	850	18.46 million	17.43 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable

FPRX, ARAV, MNPR, NATR, and OVID Headlines

Recent News About These Companies

Ovid Therapeutics Approves Key Proposals at Annual Meeting

July 10, 2025 | tipranks.com

Ovid Therapeutics Inc. (OVID) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Ovid Therapeutics Inc Chart - Morningstar

July 2, 2025 | morningstar.comM

Juneberry Farm in Ovid opens for u-pick season

July 1, 2025 | fingerlakes1.comF

Ovid man, 81, charged with DWI after near-crash

June 28, 2025 | fingerlakes1.comF

Ovid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - Nasdaq

June 27, 2025 | nasdaq.com

Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million - Nasdaq

June 27, 2025 | nasdaq.com

Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

June 25, 2025 | finanznachrichten.de

Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million

June 25, 2025 | quiverquant.comQ

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

June 25, 2025 | globenewswire.com

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

June 20, 2025 | msn.com

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

June 5, 2025 | taiwannews.com.twT

Ovid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander Rotenberg

June 5, 2025 | quiverquant.comQ

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

May 8, 2025 | cambridgenetwork.co.ukC

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

May 6, 2025 | zacks.com

Ovid Police Chief, city accused of civil rights violations

April 24, 2025 | msn.com

Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

April 23, 2025 | theglobeandmail.com

Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts

April 10, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

FPRX, ARAV, MNPR, NATR, and OVID Company Descriptions

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)

As of 07/11/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Monopar Therapeutics NASDAQ:MNPR

$43.73 +6.86 (+18.61%)

Closing price 04:00 PM Eastern

Extended Trading

$44.36 +0.63 (+1.43%)

As of 06:55 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Nature's Sunshine Products NASDAQ:NATR

$15.79 +0.17 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$15.78 0.00 (-0.03%)

As of 04:05 PM Eastern

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

Ovid Therapeutics NASDAQ:OVID

$0.40 -0.01 (-2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.39 -0.01 (-1.49%)

As of 07:45 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time